Business Club April 2 hearing San Jing Pharmaceutical released its annual report on the evening of March 31st. The company achieved operating income of RMB 30.05 billion in 2010, an increase of 13.9% year-on-year; net profit of RMB 334 million, a year-on-year increase of 19.74%; earnings per share of RMB 0.8635 . The company plans to transfer 5 shares for every 10 shares and send 4.9 yuan (including tax).
The company stated that with the introduction of the 12th Five-Year Plan on biopharmaceuticals, accelerating the reform of medical services, and the restructuring of the pharmaceutical industry, the pharmaceutical industry will usher in a new round of development opportunities. In the next 3-5 years, with the sinking of medical resources, the realization of the “Universal Medicare†ahead of schedule, and the implementation of the basic drug system in the substantive implementation stage, the grassroots consumer market with huge potential will be shaken, and the pharmaceutical industry is expected to continue its rapid growth.
It is worth noting that the annual report shows that the two funds of the Posts Department lurked in the stock in the fourth quarter of last year, of which China Post’s core growth (590,002, the fund) holds 13.72 million shares ranked among the third largest circulating shareholders, while the core themes of China Post are held. There are 123 million shares. Last year, the China Postal Service successfully lurked in the restructuring of the friendship stocks (600,827 shares), making 6.6 billion in three trading days.
Sanjing Pharmaceutical Co., Ltd. rose nearly 50% in October last year, and it is not unrelated to the establishment of the China Post Fund. However, the stock price fell sharply in the following two months.
The entry of the Chinese postal department into Sanjing Pharmaceuticals is also optimistic about its restructuring expectation. Sankyo Pharmaceutical's announcement on the suspension of major events on December 29 last year also confirmed this.
On February 16 this year, Harbin Pharmaceutical announced the issuance of additional Sanjing Pharmaceuticals and Harbin Pharmaceuticals, to achieve the overall listing of the group. After the resumption of trading of Sanjing Pharmaceuticals, which was suspended for nearly two months, it rose by 17% in two trading days. However, the performance of the stock has been sluggish for two days after it rose.
Based on the average price of 24 yuan in the fourth quarter, Sanjing Pharmaceuticals closed at 21.52 yuan on Thursday.
The company stated that with the introduction of the 12th Five-Year Plan on biopharmaceuticals, accelerating the reform of medical services, and the restructuring of the pharmaceutical industry, the pharmaceutical industry will usher in a new round of development opportunities. In the next 3-5 years, with the sinking of medical resources, the realization of the “Universal Medicare†ahead of schedule, and the implementation of the basic drug system in the substantive implementation stage, the grassroots consumer market with huge potential will be shaken, and the pharmaceutical industry is expected to continue its rapid growth.
It is worth noting that the annual report shows that the two funds of the Posts Department lurked in the stock in the fourth quarter of last year, of which China Post’s core growth (590,002, the fund) holds 13.72 million shares ranked among the third largest circulating shareholders, while the core themes of China Post are held. There are 123 million shares. Last year, the China Postal Service successfully lurked in the restructuring of the friendship stocks (600,827 shares), making 6.6 billion in three trading days.
Sanjing Pharmaceutical Co., Ltd. rose nearly 50% in October last year, and it is not unrelated to the establishment of the China Post Fund. However, the stock price fell sharply in the following two months.
The entry of the Chinese postal department into Sanjing Pharmaceuticals is also optimistic about its restructuring expectation. Sankyo Pharmaceutical's announcement on the suspension of major events on December 29 last year also confirmed this.
On February 16 this year, Harbin Pharmaceutical announced the issuance of additional Sanjing Pharmaceuticals and Harbin Pharmaceuticals, to achieve the overall listing of the group. After the resumption of trading of Sanjing Pharmaceuticals, which was suspended for nearly two months, it rose by 17% in two trading days. However, the performance of the stock has been sluggish for two days after it rose.
Based on the average price of 24 yuan in the fourth quarter, Sanjing Pharmaceuticals closed at 21.52 yuan on Thursday.
Accelerate Freeze Dried Fig is made of selected ripe figs. The international advanced ultra-low temperature FD technology is adopted to sublime the water content of fruit, without changing the fruit color, shape and flavor. Retaining the original nutritional and medicinal components, without any additive, pigment, sweetener or preservative, it is the best-quality dried fruit. Accelerate Dried Fig won the Silver Medal at the [2017 China Characteristic Tourist Commodity Contest", as well as the [Gold Medal" of [Lishang Weihai" Most Characteristic Tourist Commodity.
Freeze Dried Fig
Fig
WEIHAI ACCELERATE BIOTECHNOLOGY CO, LTD , https://www.accelerfig.com